logo
AI could lead to patient harm, researchers suggest

AI could lead to patient harm, researchers suggest

Yahoo11-04-2025
Artificial intelligence (AI) could lead to patient harm if the development of models is focused more on accurately predicting outcomes than treatment, researchers have suggested.
Experts warned the technology could create 'self-fulfilling prophecies' when trained on historic data that does not account for demographics or the under-treatment of certain medical conditions.
They added that the findings highlight the 'inherent importance' of applying 'human reasoning' to AI decisions.
Academics in the Netherlands looked at outcome prediction models (OPMs), which use a patient's individual features such as health history and lifestyle information, to help medics weigh up the benefits and risks of treatment.
AI can perform these tasks in real-time to further support clinical decision-making.
The team then created mathematical scenarios to test how AI may harm patient health and suggest that these models 'can lead to harm'.
'Many expect that by predicting patient-specific outcomes, these models have the potential to inform treatment decisions and they are frequently lauded as instruments for personalised, data-driven healthcare,' researchers said.
'We show, however, that using prediction models for decision-making can lead to harm, even when the predictions exhibit good discrimination after deployment.
'These models are harmful self-fulfilling prophecies: their deployment harms a group of patients, but the worse outcome of these patients does not diminish the discrimination of the model.'
The article, published in the data-science journal Patterns, also suggests the development of AI model development 'needs to shift its primary focus away from predictive performance and instead toward changes in treatment policy and patient outcome'.
Reacting to the risks outlined in the study, Dr Catherine Menon, a principal lecturer at the University of Hertfordshire's department of computer science, said: 'This happens when AI models have been trained on historical data, where the data does not necessarily account for such factors as historical under-treatment of some medical conditions or demographics.
'These models will accurately predict poor outcomes for patients in these demographics.
'This creates a 'self-fulfilling prophecy' if doctors decide not to treat these patients due to the associated treatment risks and the fact that the AI predicts a poor outcome for them.
'Even worse, this perpetuates the same historic error: under-treating these patients means that they will continue to have poorer outcomes.
'Use of these AI models therefore risks worsening outcomes for patients who have typically been historically discriminated against in medical settings due to factors such as race, gender or educational background.
'This demonstrates the inherent importance of evaluating AI decisions in context and applying human reasoning and assessment to AI judgments.'
AI is currently used across the NHS in England to help clinicians read X-rays and CT scans to free up staff time, as well as speeding up the diagnosis of strokes.
In January, Prime Minister Sir Keir Starmer pledged that the UK will be an 'AI superpower' and said the technology could be used to tackle NHS waiting lists.
Ian Simpson, a professor of biomedical informatics at the University of Edinburgh, highlighted that AI OPMs 'are not that widely used at the moment in the NHS'.
'Here they tend to be used in parallel with existing clinical management policies and often either for assisting diagnostics and/or speeding up processes like image segmentation,' he said.
Ewen Harrison, a professor of surgery and data science and co-director of the centre for medical informatics at the University of Edinburgh, said: 'While these tools promise more accurate and personalised care, this study highlights one of a number of concerning downsides: predictions themselves can unintentionally harm patients by influencing treatment decisions.
'Say a hospital introduces a new AI tool to estimate who is likely to have a poor recovery after knee replacement surgery. The tool uses characteristics such as age, body weight, existing health problems and physical fitness.
'Initially, doctors intend to use this tool to decide which patients would benefit from intensive rehabilitation therapy.
'However, due to limited availability and cost, it is decided instead to reserve intensive rehab primarily for patients predicted to have the best outcomes.
'Patients labelled by the algorithm as having a 'poor predicted recovery' receive less attention, fewer physiotherapy sessions and less encouragement overall.'
He added that this leads to a slower recovery, more pain and reduced mobility in some patients.
'These are real issues affecting AI development in the UK,' Prof Harrison said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Millions of people ‘could be denied weight-loss jabs due to flawed NHS guidance'
Millions of people ‘could be denied weight-loss jabs due to flawed NHS guidance'

Yahoo

time27 minutes ago

  • Yahoo

Millions of people ‘could be denied weight-loss jabs due to flawed NHS guidance'

Millions of people could be denied access to treatments such as weight-loss jabs because of flawed NHS guidance, a major think tank has warned. King's Fund senior analyst Danielle Jefferies said Body Mass Index (BMI) measures, which are used to determine obesity levels, are primarily based on research for white European or American people. That means they do not account for the inherited ethnic differences of people from Black, Asian, brown, dual heritage or indigenous ethnicities – differences that can mean some groups are more likely to develop some health conditions. The 2021 census for England and Wales showed 1.3 million people listed themselves as 'other' for their ethnic group, while 1.7 million people listed themselves in 'mixed or multiple' categories. Ms Jefferies said that meant the current BMI thresholds 'potentially do not fully work for up to 3 million people in the UK', meaning they could miss out on treatments because they have a lower BMI than is required for some treatments. The warning comes as the NHS prepares to roll out access to weight-loss jab Mounjaro, to 220,000 people over three years. Access to Mounjaro is based on strict measures, including the stipulation that a person has a BMI of over 40. Other NHS treatments, such as IVF, bariatric surgery, and joint replacement surgery, are also managed based on a person's BMI. Currently, BMI guidelines for people from black, Asian and Middle Eastern backgrounds are lowered to account for health risks that occur at a lower BMI than for white people. But it is not clear if the same is not done for those in these mixed heritage groups. Ms Jeffries said: 'The current NICE guidelines take a broad-brush approach by recommending lower BMI thresholds for anyone of Black, Asian or Middle Eastern background, which effectively includes almost everyone who is not white. 'This creates some knotty issues. First, because it leaves some people wondering if they are 'white enough' to use the old thresholds, which is a subjective and problematic way to categorise people from global majority ethnic backgrounds.' 'For example, does this include people who identify as Latino, white Middle Eastern, or Hispanic? Or does this include someone who is mixed and has one grandparent who is Black or Asian and the rest white?' Ms Jefferies said the NHS BMI calculator automatically gives patients who identify as 'other white ethnic group' – for example, someone who could identify as Latino – a higher threshold as if they were white. She said this can have 'real-world consequences' and including or excluding an ethnic group from the threshold adjustment could 'significantly impact national obesity figures and change how we measure health inequalities between different ethnicities'. 'For individuals, lower BMI thresholds could be life-changing. For the average-height adult, the cut-off point for being obese for people from a white ethnicity is more than a stone heavier than for people from a Black, Asian or Middle Eastern background. That could be significant if that person was sat in a GP appointment asking whether they qualify for bariatric surgery or weight-loss drugs, or if they are healthy enough to receive NHS-funded IVF,' she added. On Thursday, it was revealed that the price of Mounjaro will nearly triple for private patients in the UK, after the US-owned company equalised costs in markets across the globe. A month's supply of the highest doses of the 'King Kong' of weight-loss medicine will rise from £122 to £330 – an increase of 170 per cent. However, drug manufacturer Lilly said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. A NICE spokesperson said: 'We recognise that BMI is not a perfect tool and there is a need for more robust information about effective and acceptable approaches to identifying people from ethnic minority backgrounds who are at risk from overweight or obesity. 'Our independent guideline committee has called for research to find what approaches are effective and acceptable in identifying overweight, obesity and central adiposity in children, young people and adults from ethnic minority backgrounds which will help inform future NICE guidance.' This story was updated with a comment from NICE at 8:56.

Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage

Yahoo

time32 minutes ago

  • Yahoo

Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage

Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections. The company recently secured additional Medicare reimbursement for its aprevo personalized interbody implants for cervical fusion procedures, effective October 1, enhancing its financial outlook. This favorable reimbursement, granted through the Centers for Medicare & Medicaid Services' (CMS) New Technology Add-On Payment (NTAP) program in the Hospital Inpatient Prospective Payment Systems (IPPS) Final Rule for fiscal year 2026, means cervical fusion procedures using aprevo devices will be eligible for an additional $21,125 beyond standard Medicare Severity-Diagnosis-Related Groups (MS-DRGs) for qualifying inpatient benefit extends to private payors as well, utilizing unique ICD-10-PCS procedure codes. Carlsmed, which priced its initial public offering of 6.7 million shares at $15 per share in July, focuses on AI-enabled personalized spine surgery solutions. Its aprevo cervical system, having received FDA Breakthrough Device designation, is anticipated for a U.S. commercial launch in of America Securities (BofA) has initiated coverage on Carlsmed with a Buy rating and a price forecast of $16, recognizing the company's potential to establish a new standard of care in spine fusion. BofA analyst Travis Steed highlighted Carlsmed's differentiated technology and robust outlook, assigning a premium valuation of 5x 2026 estimated revenue. This premium, higher than recent medtech IPOs and other spine companies, is justified by Carlsmed's projected high revenue growth and strong gross margin profile. BofA conservatively forecasts Carlsmed will add around 20-25 new surgeons each quarter through 2027, indicating a steady increase in adoption. Carlsmed forecasts impressive top-line growth: 66% in 2025 and an annual 40-45% through 2028. Its asset-light business model is expected to support profitability, with gross margins in the mid-70s and capital expenditures at just 1% of sales, significantly lower than the approximately 10% for traditional spine peers. BofA estimates the total spine market at roughly $1.4 billion, with a compound annual growth rate (CAGR) of approximately 1.5%. In the first quarter of 2025, the global spine market (including biologics) saw 2.6% organic growth, driven by a 4.1% increase in the U.S. market. Despite the market being largely commoditized and dominated by major players like Medtronic Plc (NYSE:MDT), Globus Medical Inc (NYSE:GMED), Alphatec Holdings Inc. (NASDAQ:ATEC), Johnson and Johnson (NYSE:JNJ), and Orthofix Medical Inc. (NYSE:OFIX) (who collectively hold about 70% of the market), spine surgeons notably favor new technology. The remaining 30% of the market is split among many smaller companies, creating an opportunity for new market entrants with disruptive technology like Carlsmed's to gain traction. BofA sees significant market share capture potential for Carlsmed, with analyst Steed estimating total revenue of $133 million in 2028, representing only about 1% of the total U.S. spine market. Price Action: CARL stock is trading higher by 0.88% to $13.70 at last check Monday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

Clean and harmonised CRM data vital for AI model training
Clean and harmonised CRM data vital for AI model training

Yahoo

time3 hours ago

  • Yahoo

Clean and harmonised CRM data vital for AI model training

As healthcare entities move towards the deployment of artificial intelligence (AI) models to streamline patient engagement, being acquitted of good customer relationship management (CRM) system data is of rising importance, an expert has said. In April 2025, the UK National Health Service (NHS) released guidance on the importance of using high-quality data in training AI models. The guidance highlighted that poor quality data can lead to unintended biases and other inaccuracies that may stymy the effectiveness of AI models used for varying functions in healthcare systems. CRM data includes information on patient demographics, individuals' medical history, insurance information, billing details, and more. The consolidation of this data is intended to improve patient engagement, personalise care, and track individuals' medical history. A 2022 report indicated that revenue streams from 44% of healthcare respondents were directly affected bypoor quality CRM data. In addition, 69% of respondents said their organisations did not pursue or complete potentially valuable initiatives due to low-quality CRM data. According to Rachel Mak-McCully, senior data scientist at digital twin developer the cleaning and harmonisation of CRM datasets is not an area that is given enough consideration – despite its significant influence on AI models being deployed in healthcare. 'In thinking about clean data, there's a few issues, including how accurate and comprehensive the data is,' Mak-McCully told Medical Device Network. 'In the US, we have a very fractured medical system, so the information that you get about someone may be quite fractured.' Fractured data can relate to data that is missing because it hasn't been collected at the same time or stored together, Mak-McCully said, or in the sense that it's been measured in different ways. 'Imagine the data cleaning process as a spreadsheet. You might have a lot of different columns that are named differently, but they're the same thing. You want to make sure that all of those are harmonised into the same column,' Mak-McCully said. 'And you want to make sure that the units that you're measuring across a range of different data sources are the same. The ultimate goal is to have a clean, tabular dataset at the end that incorporates all relevant sources of data, so that a single, clean source of data can be used to train your AI model.' Mak-McCully concludes that while there is a lot of talk about the performance of AI models in healthcare and other areas, such as the new benchmarks that have been made, very few people talk about the underlying data. 'For us to clearly communicate what it is that we're doing, the implications of that and for people to understand how data is used, particularly in healthcare, is a really important conversation.' "Clean and harmonised CRM data vital for AI model training" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store